R
Replimune
Develops immunotherapies for cancer treatment
About Replimune
Replimune is at the forefront of developing advanced cancer treatments through oncolytic immunotherapies. These innovative therapies use engineered viruses to selectively infect and destroy cancer cells while simultaneously stimulating a robust immune response against tumors. By combining multiple mechanisms of action, Replimune's treatments aim to enhance the effectiveness of existing immune checkpoint inhibitors, positioning their approach as a critical component in the evolving landscape of immuno-oncology.
Replimune primarily serves patients battling various forms of cancer, working closely with healthcare providers and research institutions. The company operates within the highly specialized and competitive biotechnology sector, focusing on the development and commercialization of novel cancer therapies.
Replimune's business model revolves around the research, development, and clinical testing of its proprietary oncolytic immunotherapies. Revenue generation is anticipated through partnerships, licensing agreements, and eventual sales of approved therapies. The company invests heavily in clinical trials to validate the efficacy and safety of its treatments, aiming to bring transformative cancer therapies to market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Woburn, United States
- Listing
- IPO 2018
- Employees
- 352
- Open positions
- 36
- Dealroom signal
- 62.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2024 | $100M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Dec 2022 | $260M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$316M | — |
| 2025 | $0 | — | −$257M | — |
| 2024 | $0 | — | −$229M | — |
| 2023 | $0 | — | −$177M | — |
| 2022 | — | — | −$114M | — |
| 2021 | — | — | −$76M | — |
| 2020 | — | — | −$53M | — |
Growth signals
Latest recorded traffic for Replimune is 14K monthly website visits, down 17.6% over the last three months. Replimune's team declined 23.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Atlas Venture
Forbion Capital Partners
Omega Funds
Foresite Capital
Bain Capital Life Sciences
Cormorant Asset Management
Redmile Group
Transformation Capital
Series B and later1 investor entered at this stage
Hercules Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Replimune on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Replimune’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.